Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Tau protein and amyloid s (Abeta), two major components of neuropathology in Alzheimer disease (AD), have been applied for establishment of more useful biomarkers and therapeutic approaches. Total tau protein in CSF is a biomarker for AD, however increased levels of total tau in CSF were also observed in other neurological disease with dementia. Phosphorylation is an important feature of tau protein and phosphorylated tau in CSF is useful to distinguish AD from other disease.

What this study adds

Evidence grade: Low

This paper discusses tau and amyloid as biomarkers and explores possible neuroprotective strategies for Alzheimer's disease, including a mechanism of amyloid toxicity involving down-regulation of XIAP. It is a broad biological discussion, not a clinical demonstration that any treatment, cure or prevention works in people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tanaka, T., Isoe-Wada, K., Yamamori, H., Kato, K., Nessa, B. N., Sadik, G. M., et al. (2006). Neurobiological studies of dementia--biological markers and neuroprotective strategies for Alzheimer disease. Acta neurologica Taiwanica.

Vancouver

Tanaka T, Isoe-Wada K, Yamamori H, Kato K, Nessa BN, Sadik GM, et al. Neurobiological studies of dementia--biological markers and neuroprotective strategies for Alzheimer disease. Acta neurologica Taiwanica. 2006. PMID: 16599295.

BibTeX

@article{tanaka2006-16599295,
  author  = {Tanaka, T. and Isoe-Wada, K. and Yamamori, H. and Kato, K. and Nessa, B. N. and Sadik, G. M. and Takeda, M.},
  title   = {{Neurobiological studies of dementia--biological markers and neuroprotective strategies for Alzheimer disease}},
  journal = {Acta neurologica Taiwanica},
  year    = {2006},
  pmid    = {16599295}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This paper discusses tau and amyloid as biomarkers and explores possible neuroprotective strategies for Alzheimer's disease, including a mechanism of amyloid toxicity involving down-regulation of XIAP. It is a broad biological discussion, not a clinical demonstration that any treatment, cure or prevention works in people.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 26 of the 96 points it could be judged on, which is 27 of 100. Total 27 of 100.26 of the 96 points we could judge = 27 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Acta neurologica Taiwanica)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2006 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.1 citations a year over 22 year(s) since 2006
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Masatoshi Takeda: h-index 69 (OpenAlex, whole career)
Institution's track record 1 / 3 The University of Osaka: institution h-index 1,138 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 16599295)
Free to read 0 / 2 Behind a paywall — scores zero
Points 26 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100.
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →